Phase 1a, Randomized, Double-blinded, Placebo-controlled, Single-dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ELX-02 in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 19 Mar 2018
At a glance
- Drugs ELX 02 (Primary)
- Indications Inborn genetic disorders
- Focus Adverse reactions; First in man
- Sponsors Eloxx Pharmaceuticals
- 19 Mar 2018 According to an Eloxx Pharmaceutical media release, results from the completed Phase 1 SAD study (NCT02807961 and NCT03292302) will be included in the planned IND and CTA submissions.
- 02 Jun 2017 According to an Eloxx Pharmaceutical, Inc. media release, status changed from recruiting to completed.
- 05 Jul 2016 New trial record